Clinical Discussion Series
|Selecting Patients for Maintenance or Continuous Therapy Including Regimen Selection and Duration of Treatment|
Philip McCarthy, MD
|Release Date: October 07, 2015|
Expiration Date: October 07, 2016
Reviewed: January 17, 2017 for clinical relevance; CE is expired.
Join team Managing Myeloma world expert Philip McCarthy, MD, professor of oncology and the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York, as he reviews Managing Myeloma member responses to a recent survey regarding use of maintenance therapy in their practice. As part of Dr. McCarthy’s discussion, he provides an overview of current clinical data supporting specific maintenance strategy approaches after transplant, continuous therapy in non-transplant patients, as well as safety considerations. He also discusses some new approaches that are emerging from clinical trials.Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Takeda Oncology and Celgene Corporation